In this article, we will take a look at some of the best dividend stocks.Drug pricing has become one of the biggest pressure points for pharmaceutical companies this year, as the U.S. moves to rein in what consumers pay at the pharmacy counter.For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other developed countries. Branded medicines carry even steeper premiums. That gap explains why so much of the industry’s revenue still depends on Amer ...

记者丨刘夏菲 编辑丨巫燕玲 2025年，香港交易所的上市锣声格外密集。 若以全年117家新上市公司计算，平均每两个交易日，就有一声鸣锣在维港畔响起。 "含A量"提升 据德勤中国市场服务部预测，2025年港股IPO市场融资额预计将达2863亿港元（约360亿美元），超越纳斯达克全年预期，锁定全球 第一。 港股IPO规模扩张的背后，一批大型IPO项目贡献了绝对力量。 而聚焦2025年港股募资额前十大IPO企业，一个值得关注的现象是，其中有6家都是"A＋H"上市企业。 从动力电池龙头宁德时代，到医药巨头恒瑞医药，再到消费白马海天味业，以及三一重工、赛力斯、三花智控等行业龙头，仅这6家 公司的合计募资额就高达1033.20亿港元，贡献了港股全年IPO募资额的36.12%。 此外，募资规模位列第二的紫金黄金国际，则由A股公司紫金矿业分拆而来。 伴随着密集的锣声，全球资本市场的目光再次聚焦于此—— 时隔数年，港股市场以预计超过2800亿港元的IPO募资总额，重夺全球 募资榜首 。 这一年，恰逢港交所成立二十五周年。走过四分之一世纪，港股此番"王者归来"，在IPO融资规模重新登顶之外，市场的核心叙事也 已悄然生变。 聚焦港 ...

Group 1 - Bernstein SocGen Group reiterated its Outperform rating and $135 price target on Gilead Sciences, citing limited financial exposure to recent Medicaid pricing developments [1] - Only certain products, representing about 60% of Gilead's portfolio, were aligning with MFN pricing for Medicaid, specifically Genvoya and Odefsey, which together generated approximately $750 million in Medicaid gross spend in 2023 [2] - Concerns around Medicaid pricing risk for Biktarvy were alleviated, with negotiations resulting in a favorable outcome, and the estimated 2026 revenue impact for Genvoya and Odefsey combined is expected to be minimal, less than $200 million, and in the low single-digit percentage range for the overall company [3]

Core Viewpoint - The article highlights a pending securities class action lawsuit against Telix Pharmaceuticals Ltd. due to alleged misstatements regarding the company's therapeutic candidates and supply chain reliability, leading to significant investor losses [1][2][3]. Regulatory Setbacks - Telix Pharmaceuticals faced multiple regulatory challenges, including an SEC subpoena and a Complete Response Letter (CRL) from the FDA, which resulted in a 21% decline in stock value following the final news [2][7]. - The SEC is investigating the company's disclosures related to the development of its prostate cancer therapeutic candidates, suggesting potential misleading statements [7]. Allegations of Misrepresentation - The lawsuit claims that Telix and its executives overstated the developmental progress of their therapeutic candidates and misrepresented the reliability of their third-party supply chain and manufacturing partners [2][3]. - The complaint alleges that the SEC questioned the development disclosures, while the FDA rejected a Biologics License Application (BLA) due to deficiencies in Chemistry, Manufacturing, and Controls (CMC) [3][7]. Investor Impact - The cumulative effect of the regulatory disclosures reportedly caused significant financial damage to investors who purchased Telix ADSs during the Class Period from February 21, 2025, to August 28, 2025 [7]. - The firm Hagens Berman is actively advising affected investors to discuss their rights and potential recovery options [4][5].

NEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team: ht ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Group 1 - The article discusses Edgewise Therapeutics, Inc. (EWTX) and its ongoing development of EDG-7500 despite safety concerns related to atrial fibrillation (AF) [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and provides in-depth analysis through the Biotech Analysis Central service, which includes a library of over 600 articles and a model portfolio of small and mid-cap stocks [2] - The service is available for a monthly fee of $49, with a discounted annual plan at $399, offering a 33.50% savings [1] Group 2 - The article does not contain any specific financial data or performance metrics related to Edgewise Therapeutics or its products [4] - There are no disclosed positions or plans to invest in the companies mentioned, indicating an unbiased perspective in the analysis [3]

Core Insights - The U.S. stock market has faced significant volatility in early 2025 due to trade policy changes under the new Trump administration, aggressive tariffs, and growing Sino-U.S. trade tensions [1][2] - The federal reserve rate cuts have lowered borrowing costs, positively impacting corporate profitability despite rising manufacturing costs and supply chain issues [2][3] Market Conditions - Trade-related risks and changes in monetary policy have led to frequent stock price fluctuations, but tech stocks have driven positive market momentum [3] - The overall annual inflation rate in 2025 was lower than expected despite a hike in energy prices [3] Growth Drivers for 2026 - Rapid AI infrastructure buildouts are anticipated to be a key growth driver across various industries, requiring substantial investment in computing infrastructure and data centers [4] - Companies with stable earnings and robust cash flow are expected to benefit from the emerging trends in AI investment [4] Company Highlights - **IBM**: Positioned as a major player in the AI landscape, with a free cash flow of $2.37 billion in Q3 2025, and a quarterly dividend of $1.68 per share, yielding 2.2% [7][9][10] - **Analog Devices, Inc. (ADI)**: Benefiting from strong growth in industrial and defense sectors, with an operating cash flow of $4.81 billion in fiscal 2025 and a quarterly dividend of 99 cents per share, yielding 1.43% [12][13][14] - **Johnson & Johnson (JNJ)**: Expected accelerated growth in its Innovative Medicine segment, with $17.22 billion in cash from operating activities and a quarterly dividend of $1.3 per share, yielding 2.5% [15][16] - **The Gap, Inc. (GAP)**: Strong brand performance and market share growth, with net cash from operating activities of $607 million and a quarterly dividend of 16 cents per share, yielding 2.52% [19][20] - **Hewlett Packard Enterprise (HPE)**: Benefiting from traction in the AI networking market, generating $2.5 billion in cash from operating activities and a quarterly dividend of 14 cents per share, yielding 2.33% [21]

Core Viewpoint - Jim Cramer recommends three dividend stocks: Enbridge Inc., Pfizer, and Realty Income, highlighting their strong fundamentals and potential for long-term growth despite market volatility [1][2]. Enbridge Inc. - Enbridge is an oil pipeline company that focuses on the volume of oil transported rather than commodity prices, serving over 7 million U.S. customers [3][4]. - The company has a dividend yield of 5.98%, trading at $47.53, and is expected to add $8 billion in new projects next year, which could enhance cash flow and dividend payouts [5]. - Enbridge has raised its dividends for two consecutive years, paying an annual dividend of $2.84, and is considered to have a low-risk business model with strong fundamentals [5]. Pfizer Inc. - Pfizer is recognized as a dividend giant with a yield of 6.86%, viewed as a "bond equivalent" by Cramer, providing stable returns despite limited share price appreciation [6][7]. - The company has made strategic acquisitions, including Seagen and Metsera, to strengthen its drug pipeline and address patent expirations [7]. - Pfizer generated $14 billion in free cash flow this year, has a payout ratio of 53.13%, and has increased dividends for 15 consecutive years, with a 5-year dividend growth rate of 3.62% [8]. Realty Income - Realty Income is a REIT that leases commercial properties, offering a yield of 5.7% and known as 'The Monthly Dividend Company' [9][10]. - The company has a high occupancy rate of 98.7% and owns 15,500 single-tenant properties, demonstrating resilience even in weaker consumer spending environments [10][11]. - Realty Income has raised its dividend four times this year, pays an annual dividend of $3.24, and has a 4.2% annualized growth rate over the past three decades, making it a reliable high-yield dividend stock [10][11].

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply on Monday.Mereo BioPharma and its partner Ultragenyx revealed results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI). Osteogenesis Imperfecta (OI) includes a group of genetic disorders impacting bone metabolism. The collagen mutations in OI can result in increased bone brittleness, which contributes to a high rate of fractures.Ultragenyx Pharmaceutical shares dipped 42% to $19.84 on Monday.H ...